Visceral adiposity index is associated with significant fibrosis in patients with non‐alcoholic fatty liver disease

Aliment Pharmacol Ther 2012; 35: 238–247

[1]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[2]  J. Kench,et al.  Beyond insulin resistance in NASH: TNF‐α or adiponectin? , 2004, Hepatology.

[3]  Massimo Midiri,et al.  Visceral Adiposity Index , 2010, Diabetes Care.

[4]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[5]  M. Gambardella,et al.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.

[6]  P. Abreu-González,et al.  Relation between Body Fat and Liver Fat Accumulation and Cytokine Pattern in Non-Alcoholic Patients with Chronic HCV Infection , 2009, Annals of Nutrition and Metabolism.

[7]  J. George,et al.  Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis , 2006, Hepatology.

[8]  H. Tilg,et al.  Adiponectin and its receptors in non-alcoholic steatohepatitis , 2004, Gut.

[9]  A. Craxì,et al.  Reliability of liver stiffness measurement in non‐alcoholic fatty liver disease: the effects of body mass index , 2011, Alimentary pharmacology & therapeutics.

[10]  G. Watts,et al.  Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men , 2006, Diabetes, obesity & metabolism.

[11]  G. Marchesini,et al.  High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[12]  A. Feldstein,et al.  Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis , 2008, The American Journal of Gastroenterology.

[13]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[14]  J. Kench,et al.  Visceral fat: A key mediator of steatohepatitis in metabolic liver disease , 2008, Hepatology.

[15]  S. Caldwell,et al.  Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[16]  Carla Giordano,et al.  Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1 , 2010, Hepatology.

[17]  P. Newsome,et al.  Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis , 2010, Alimentary pharmacology & therapeutics.

[18]  A. Craxì,et al.  Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. , 2010, Current pharmaceutical design.

[19]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[20]  Y. Ikeda,et al.  Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. , 2001, Endocrine journal.

[21]  A. Craxì,et al.  Non-alcoholic fatty liver disease pathogenesis: the present and the future. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[22]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[23]  A. Clouston,et al.  Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis , 1999, Hepatology.

[24]  A Tremblay,et al.  Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. , 1994, The American journal of cardiology.

[25]  G. Pacini,et al.  Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease , 2005, Hepatology.

[26]  Ja-june Jang,et al.  Visceral adipose tissue area is an independent risk factor for hepatic steatosis , 2008, Journal of gastroenterology and hepatology.

[27]  Laura Herrero,et al.  Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.

[28]  J. Crespo,et al.  Gene expression of tumor necrosis factor α and TNF‐receptors, p55 and p75, in nonalcoholic steatohepatitis patients , 2001 .

[29]  J. Després,et al.  Abdominal obesity and metabolic syndrome , 2006, Nature.

[30]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[31]  Jimmy D Bell,et al.  Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study , 2004, Gut.

[32]  A. Craxì,et al.  Hyperuricemia is associated with histological liver damage in patients with non‐alcoholic fatty liver disease , 2011, Alimentary pharmacology & therapeutics.

[33]  G. Leandro,et al.  Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. , 2003, Journal of hepatology.

[34]  Y. Yılmaz.  Systematic review: caspase‐cleaved fragments of cytokeratin 18 – the promises and challenges of a biomarker for chronic liver disease , 2009, Alimentary pharmacology & therapeutics.

[35]  H. Tilg,et al.  Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. , 2006, Gastroenterology.

[36]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[37]  R. Rodrigo,et al.  Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. , 2006, Cytokine.

[38]  R. Rodrigo,et al.  Increased production of IL-1α and TNF-α in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease , 2006 .